Valuation: Agenus Inc.

Market Cap 337M 289M 269M 247M 464M 32.27B 474M 3.2B 1.25B 16.17B 1.27B 1.24B 53.53B P/E 2026 *
11x
P/E 2027 * -30.6x
Enterprise Value 337M 289M 269M 247M 464M 32.27B 474M 3.2B 1.25B 16.17B 1.27B 1.24B 53.53B EV / Sales 2026 *
2.4x
EV / Sales 2027 * 2.46x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-9.32%
1 week+7.00%
Current month-0.13%
1 month+50.70%
3 months+137.78%
6 months+144.77%
Current year+138.54%
1 week 6.96
Extreme 6.9601
8.73
1 month 5.46
Extreme 5.46
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
31.2
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/8/26 Free

Chief Executive Officer

1,971,500 4.4054%
5/8/26 Free

Director

50,000 0.1117%
5/8/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
-9.32%+7.00%+66.08%-74.52% 337M
+1.14%+2.27%+2.38%+24.14% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
+3.06%+3.88%+5.81%+35.00% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average -0.64%+3.61%+82.80%+105.58% 27.55B
Weighted average by Cap. +0.20%+3.18%+103.41%+150.53%

Financials

2026 *2027 *
Net sales 140M 120M 112M 103M 193M 13.42B 197M 1.33B 518M 6.73B 527M 515M 22.27B 137M 118M 110M 101M 189M 13.14B 193M 1.3B 507M 6.59B 516M 505M 21.81B
Net income 35.2M 30.14M 28.12M 25.8M 48.48M 3.37B 49.44M 334M 130M 1.69B 132M 129M 5.59B -26.1M -22.35M -20.85M -19.13M -35.95M -2.5B -36.66M -247M -96.42M -1.25B -98M -95.87M -4.14B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
20/08/26 USD 7.490 -9.32% 1,575,849
19/08/26 USD 8.260 +9.69% 2,290,360
18/08/26 USD 7.530 +5.31% 967,558
17/08/26 USD 7.150 -2.32% 831,412
14/08/26 USD 7.320 +4.57% 1,251,966
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.490USD
Average target price
19.50USD
Spread / Average Target
+160.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock